Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Gill, Avinash ^a,e   Scanlon, Thomas C ^a   Osipovitch, Daniel C ^b   Madden, Dean R ^b,c   Griswold, Karl E ^a,b,d  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Lamont Doherty Earth Observatory   (United States)

^e Bio Architecture Lab   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPOLYMER; LYSOZYME; RECOMBINANT ENZYME; ACTIN; ANTIINFECTIVE AGENT; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DRUG STRUCTURE; ELECTRIC POTENTIAL; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME INHIBITION; ENZYME STABILITY; ENZYME STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN INTERACTION; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PROTEIN ENGINEERING; PROTEIN PROCESSING; SEQUENCE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ACTINS; ANTI-BACTERIAL AGENTS; BIOCATALYSIS; CRYSTALLOGRAPHY, X-RAY; ENZYME STABILITY; HUMANS; MODELS, MOLECULAR; MURAMIDASE; MUTANT PROTEINS; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEQUENCE ANALYSIS, PROTEIN; STATIC ELECTRICITY;

EID: 79952336486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016788     Document Type: Article

References (32)

1. Govan JR, Nelson JW, (1992) Microbiology of lung infection in cystic fibrosis. Br Med Bull 48: 912-930.
2. Rubin BK, (2007) Mucus structure and properties in cystic fibrosis. Paediatric Respiratory Reviews 8: 4-7.
3. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA, (2008) In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells. Infect Immun 76: 1423-1433.
4. Projan SJ, (2007) (Genome) size matters. Antimicrobial Agents and Chemotherapy 51: 1133-1134.
5. Gibson RL, Burns JL, Ramsey BW, (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918-951.
6. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, et al. (2008) A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proceedings of the National Academy of Sciences 105: 15070-15075.
7. Nash JA, Ballard TNS, Weaver TE, Akinbi HT, (2006) The Peptidoglycan-Degrading Property of Lysozyme Is Not Required for Bactericidal Activity In Vivo. J Immunol 177: 519-526.
8. Cole AM, Liao H-I, Stuchlik O, Tilan J, Pohl J, et al. (2002) Cationic Polypeptides Are Required for Antibacterial Activity of Human Airway Fluid. J Immunol 169: 6985-6991.
9. Travis SM, Conway BAD, Zabner J, Smith JJ, Anderson NN, et al. (1999) Activity of abundant antimicrobials of the human airway. American Journal of Respiratory Cell and Molecular Biology 20: 872-879.
10. Shire SJ, (1996) Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme® (Dornase Alpha)]. In: Pearlman R, Wang YJ, editors. Pharmaceutical Biotechnology New York New York Kluwer Academic Publishers pp. 393-426.
11. Scanlon TC, Teneback CC, Gill A, Bement JL, Lamppa JW, et al. (2010) Enhanced antimicrobial activity of engineered human lysozyme. ACS Chemical Biology 5: 809-818.
12. Ramsey DM, Wozniak DJ, (2005) Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Molecular Microbiology 56: 309-322.
13. Rogers DF, (2007) Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respiratory Care 52: 1134-1149.
14. Ulmer JS, Herzka A, Toy KJ, Baker DL, Dodge AH, et al. (1996) Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 93: 8225-8229.
15. Weiner DJ, Bucki R, Janmey PA, (2003) The Antimicrobial Activity of the Cathelicidin LL37 Is Inhibited by F-actin Bundles and Restored by Gelsolin. Am J Respir Cell Mol Biol 28: 738-745.
16. Sanders LK, Guáqueta C, Angelini TE, Lee J-W, Slimmer SC, et al. (2005) Structure and Stability of Self-Assembled Actin-Lysozyme Complexes in Salty Water. Physical Review Letters 95: 108302.
17. Sanders LK, Xian W, Guaqueta C, Strohman MJ, Vrasich CR, et al. (2007) Control of electrostatic interactions between F-actin and genetically modified lysozyme in aqueous media. Proceedings of the National Academy of Sciences 104: 15994-15999.
18. Matthews BW, (1968) Solvent content of protein crystals. J Mol Biol 33: 491-497.
19. Kumar S, Nussinov R, (2002) Close-Range Electrostatic Interactions in Proteins. ChemBioChem 3: 604-617.
20. McGaughey GB, Gagne M, Rappe AK, (1998) Pi-Stacking Interactions: ALIVE AND WELL IN PROTEINS. Journal of Biological Chemistry 273: 15458-15463.
21. Koshiba T, Yao M, Kobashigawa Y, Demura M, Nakagawa A, et al. (2000) Structure and Thermodynamics of the Extraordinarily Stable Molten Globule State of Canine Milk Lysozyme†,‡. Biochemistry 39: 3248-3257.
22. Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, et al. (2005) ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucl Acids Res 33: W299-302.
23. Edgar RC, (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Research 32: 1792-1797.
24. Niesen FH, Berglund H, Vedadi M, (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protocols 2: 2212-2221.
25. Voynow JA, Fischer BM, Zheng S, (2008) Proteases and cystic fibrosis. The International Journal of Biochemistry & Cell Biology 40: 1238-1245.
26. Kabsch W, (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. Journal of Applied Crystallography 26: 795-800.
27. Collaborative Computational Project N (1994) The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr D Biol Crystallogr D50: 760-763.
28. Song H, Inaka K, Maenaka K, Matsushima M, (1994) Structural Changes of Active Site Cleft and Different Saccharide Binding Modes in Human Lysozyme Co-crystallized with Hexa-N-acetyl-chitohexaose at pH 4.0. Journal of Molecular Biology 244: 522-540.
29. Adams PD, Grosse-Kunstleve RW, Hung L-W, Ioerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D 58: 1948-1954.
30. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D 60: 2126-2132.
31. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera- A visualization system for exploratory research and analysis. Journal of Computational Chemistry 25: 1605-1612.
32. Higo J, Nakasako M, (2002) Hydration structure of human lysozyme investigated by molecular dynamics simulation and cryogenic X-ray crystal structure analyses: On the correlation between crystal water sites, solvent density, and solvent dipole. Journal of Computational Chemistry 23: 1323-1336.